Cardioplegia and myocardial ischemia during cardiopulmonary bypass.
Presently myocardial protection can be obtained in three main ways: 1) energy conservation through chemical induction of rapid and complete diastolic arrest, 2) slowing of the metabolic rate and degradative process through the use of hypothermia, and 3) prevention or reversal of unfavourable ischemic-induced changes with various protective agents. These methods of myocardial protection and their effectiveness, the calcium metabolism during myocardial ischemia, and the effects of calcium channel blockers are briefly reviewed and discussed. It is stressed that myocardial protection during ischemic arrest is a complex entity, and that new modes of myocardial protection are needed in the future.
D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002315:Cardiopulmonary Bypass / Q000009:adverse effects* / Q000379:methods; D002951:Citrates; D019343:Citric Acid; D003327:Coronary Disease / Q000473:pathology / Q000517:prevention & control*; D006324:Heart Arrest, Induced; D006801:Humans; D007036:Hypothermia, Induced; D009206:Myocardium / Q000648:ultrastructure
D002121:Calcium Channel Blockers; D002951:Citrates; D019343:Citric Acid; D002118:Calcium